Your doctor is ordering CancerTYPE ID

A test for unclear metastatic cancer diagnosis
When metastatic cancer diagnosis is unclear, your physician may order CancerTYPE ID to provide additional genomic information to identify the type of cancer.

**CancerTYPE ID** is a diagnostic test that may help patients with unclear diagnosis of metastatic cancer by providing your medical professional team with additional genomic information about the cancer type. This information may help your physician design a more personalized treatment plan for your disease.

**CancerTYPE ID** works by comparing genomic information taken from a sample of your tumor to a reference database of over 2,000 tumors that have been clearly diagnosed. It finds the closest match to the different tumor types in the reference database and this information is provided to your physician in a test report.
Insurance coverage for CancerTYPE ID®

Biotheranostics wants individuals and families to be able to focus on the health of the patient, and to leave the insurance process to them. The company is committed to doing all they can to help you manage any expenses related to their tests.

Biotheranostics believes every clinically eligible patient should have access to their tests, independent of insurance or financial status. The company accepts all insurance plans and has a Patient Advocate Team whose members are available to answer questions about billing or available financial assistance programs.

Medicare covers CancerTYPE ID as a medically necessary test when coverage criteria under the current Local Coverage Determinations (LCDs) are met.*

Please contact our Patient Advocate Team at (844) 319-8111 or visit CancerTYPEID.com for more detailed information about billing.


*Visit CancerTYPEID.com to see coverage criteria under the current LCD (Local Coverage Determination)
CancerTYPE ID® Intended Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.